Antengene Presents Four Preclinical Posters at AACR 2024
PR Newswire Asia
SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited (*"**Antengene**"**, *SEHK: 6996.HK), a..
SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited (*"**Antengene**"**, *SEHK: 6996.HK), a..
· *Five posters *showcased progress with multiple preclinical and clinical programs, including *ATG-008 (mTORC1/2 inhibitor),..
– *Five posters *will showcase progress with multiple preclinical and clinical programs, including the clinical results of..